| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e52120b2f1d01b0935e15fe4b5ad667c |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6889
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-537
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6855
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6851
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-48723
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6899
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 |
| filingDate |
2013-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ee4441955f484c7dcef99de8174f856f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e20d3af28452a5b61ba21716b14aa56d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e821273c97f540c26e04cebb7c28653f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1ac23041d20bc6a60852e3b25bf6837b |
| publicationDate |
2014-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2014178413-A1 |
| titleOfInvention |
Compounds and methods for the treatment of erb b2/neu positive diseases |
| abstract |
Disclosed herein are anti-ERB B2/NEU antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods relating to the preparation and uses of such drug conjugates to treat ERB B2/NEU positive cells in cancers are provided. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10526344-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9737616-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9597297-B2 |
| priorityDate |
2012-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |